Morgan Stanley Maintains Equal-Weight on Zimmer Biomet Holdings, Lowers Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Cecilia Furlong maintains an Equal-Weight rating on Zimmer Biomet Holdings (NYSE:ZBH) and lowers the price target from $150 to $140.
May 31, 2023 | 11:41 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley maintains an Equal-Weight rating on Zimmer Biomet Holdings (NYSE:ZBH) and lowers the price target from $150 to $140.
The news directly mentions Zimmer Biomet Holdings (ZBH) and the lowered price target by Morgan Stanley. This may cause some investors to reevaluate their positions, but the Equal-Weight rating suggests that the stock is fairly valued, and the impact on the stock price is expected to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100